Skip Navigation
Search Menu

Wilmer Eye Institute
Print This Page
Share this page: More

Wilmer Clinical Trial Outcomes Contribute to FDA Approval of Wavefront-Guided LASIK for Nearsightedness and Astigmatism

Wilmer laser surgeons have participated in a multicenter clinical trial which led to FDA approval of the new Visx "WaveScan" wavefront technology for LASIK treatment of mild to moderate nearsightedness and astigmatism.

In wavefront-guided LASIK, as performed at Wilmer, the patient undergoes a rigorous pre-surgical evaluation, including the new wavefront analysis, lasting up to two hours. Based on the extensive and highly detailed information obtained in the evaluation, Wilmer surgeons then plan and perform the LASIK procedure.

Trial Outcomes After Six Months

Six months after surgery, Wilmer surgeons reported the following visual outcomes for wavefront-guided LASIK:

  • 96% of treated eyes achieved uncorrected visual acuity of 20/20 or better
  • 71% of treated eyes achieved uncorrected visual acuity of 20/16 or better
  • 47% of treated eyes achieved a better  uncorrected  visual acuity than their pre-surgical  corrected  visual acuity
  • 70% of treated eyes had either a decrease or almost no change in high-order aberration
  • The procedure has an excellent safety profile.

For more information about Wilmer wavefront-guided LASIK or refractive surgery in general, please sign up for one of our free seminars or call us at 410-583-2802.